Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs

Title: Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs

Volume: 5 Issue: 1

Author(s): Farhad Jadidi-Niaragh and Abbas Mirshafiey

Affiliation:

Keywords: Multiple sclerosis, experimental autoimmune encephalomyelitis, fingolimod, FTY720, cladribine, triptolide, laquinimod, teriflunomide, fumaric acid, central nervous system, macrophages, EAE, immunization, RRMS, SPMS, PPMS, BBB, Fingolimod (FTY720), bradycardia, IFN-1a, FDA, Laquinimode, CLARITY, RA, SLE, Triperygium wilfordii, Alzheimer's disease, Parkinson disease, LLDT-8, mRNA, TGF-, (MMP)-1, (VCAM)-1, NF-AT, NF-B, NK, Th17 cells, PBMC, CD4+ T cells, DMF, MMF, NQO1, IL-10, AI, CD4+, BG00012, DEFINE, CONFIRM

Abstract: Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system and the most common cause of neurological disability in young adults, along with a considerable clinical and pathological heterogeneity. Since, current therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive phase of this disease, thus novel promising therapeutic strategies might open a light horizon in approaching to an efficient treatment in MS. In this review, we will discuss about relevant patents and novel designed immunosuppressive and anti-inflammatory oral drugs promising for treatment of multiple sclerosis.

Cite this article as:

Jadidi-Niaragh Farhad and Mirshafiey Abbas, Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs, Recent Patents on Inflammation & Allergy Drug Discovery 2011; 5 (1) . https://dx.doi.org/10.2174/187221311794474900